Inspirata, Inc. : Inspirata Announces 'End-of-Support' for Omnyx VL4 and VL120 Digital Pathology Whole Slide Image Scanners Effective May 4, 2019
Since its acquisition of Omnyx, Inspirata has been assisting Omnyx customers with the selection of next-generation scanners to use in combination with its device-agnostic IVD software.
Tampa, FL, May 11, 2018 (GLOBE NEWSWIRE) -- Cancer informatics and digital pathology workflow solution provider Inspirata®, Inc. announced today that it has provided 12-month notice officially ending support of the Omnyx® VL4 and VL120 whole slide image scanners. The "End-of-Support" notice provided to customers is effective May 4, 2019. Production of these scanners began in 2013 and ended in 2016.
"The VL4 and VL120 scanners are outdated technology," says Inspirata CEO Satish Sanan, "so we are working with existing Omnyx customers on a case-by-case basis to move them to our state-of-the-art digital pathology software and workflow solutions and assist them in selecting the most appropriate next-generation scanners based on their specific use cases.
"We are a scanner-agnostic digital pathology software and workflow solutions company, and are wholly focused on digital pathology adoption by developing, implementing and supporting innovative software that enhances the pathology workflow," continues Sanan. "Our software development teams in Tampa, Pittsburgh and Bangalore, India are busy working on combining the best features of our Digital Pathology Cockpit and the Omnyx Dynamyx(TM) software platform so that we can offer customers a converged state-of-the-art technology stack and best-in-class digital pathology workflow solution within a year."
Omnyx originally introduced the Integrated Digital Pathology (IDP) System VL4 and VL120 Scanners in 2013 but did not refresh the technology thereafter, instead focusing on bringing digital pathology software to pathology departments around the world. The company's flagship digital software product, Dynamyx(TM), enhances the pathology workflow through collaboration and other tools that boost pathologists' efficiency. The software is CE-marked in Europe and licensed by Health Canada for in vitro diagnostic (IVD) use.
About Inspirata, Inc.
Inspirata®, Inc. offers the most comprehensive cancer diagnostics workflow solution available for precision diagnosis today. The solution, which employs a unique "solution-as-a-service" business and delivery model, accelerates anatomic and molecular pathology workflows and facilitates whole slide imaging and image analytics, prognostic and predictive assays, remote consultations and tumor boards. This comprehensive solution includes an Enterprise Service Bus (ESB) to help to solve interoperability issues and a Natural Language Processing Engine (NLP) for structuring data. Inspirata amalgamates this structured data into a central multi-institutional and multi-modal big data cancer repository for clinical, research and educational purposes. Its use will extend to physicians, patients, researchers and pharma among others. This comprehensive solution facilitates a modern precision diagnosis to build a strong foundation for precision medicine. For more information, please visit www.inspirata.com or contact email@example.com.
Marjorie Bulone Inspirata, Inc. 813-570-8905 firstname.lastname@example.org
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Inspirata, Inc. via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
GlobeNewswire Test Release19.5.2018 07:00 | Pressemelding
LOS ANGELES, May 18, 2018 (GLOBE NEWSWIRE) -- This is a test from GlobeNewswire. Readers are advised to disregard. TESTING -- TESTING -- TESTING -- TESTING -- TESTING -- TESTING -- TESTING -- TESTING – -END- CONTACT: Karen Yu Director, GlobeNewswire Product Management Direct: +1 310 258 6917 Mobile: +1 626 389 7427 or Magali Rolandez Senior Manager, Media Relations/Content Distribution Europe Direct: +44 (0) 203 753 2215 Mobile: +44 (0) 7785 619 539
BK Ultrasound, Powered by Analogic, Launches bkSpecto Ultrasound System for Urology at the 2018 American Urological Association Annual Meeting18.5.2018 23:23 | Pressemelding
PEABODY, Mass., May 18, 2018 (GLOBE NEWSWIRE) -- Analogic Corporation (Nasdaq:ALOG), enabling the world's medical imaging and aviation security technology, today announced that it will launch the bkSpecto(TM) ultrasound system at the 113th AUA (American Urological Association) Annual Meeting, May 18-21, in San Francisco. bkSpecto-taken from the Latin word Specto, meaning 'I see'-is BK Ultrasound's all-new ultrasound platform designed for clinical practices. bkSpecto combines BK's advanced auto-optimization algorithms with faster processing to render exceptional anatomical imaging detail with minimal manual adjustment by the user. The system has a unique glass touch-based interface using BK's Tru-Sense(TM) technology to provide 'sightless navigation.' The interface enables tactile feedback with or without gloves, providing an intuitive, self-guided user experience. The interface is also customizable, enabling personalized and faster user workflows. The small footprint of bkSpecto makes
Brookfield Asset Management Announces Renewal of Normal Course Issuer Bid18.5.2018 12:55 | Pressemelding
TORONTO, May 18, 2018 (GLOBE NEWSWIRE) -- Brookfield Asset Management Inc. (NYSE:BAM) (TSX:BAM.A) (EURONEXT:BAMA) ("Brookfield") today announced it has received approval from the Toronto Stock Exchange ("TSX") for the renewal of its normal course issuer bid to purchase up to 82,315,909 Class A Limited Voting Shares ("Class A Shares"), representing 10% of the public float of Brookfield's outstanding Class A Shares. Purchases under the bid will be made through the facilities of the TSX, the New York Stock Exchange ("NYSE") and any alternative Canadian trading system. The period of the normal course issuer bid will extend from May 24, 2018 to May 23, 2019, or an earlier date should Brookfield complete its purchases. Brookfield will pay the market price at the time of acquisition for any Class A Shares purchased. As at May 1, 2018, the number of Class A Shares issued and outstanding totalled 991,857,711, of which 823,159,095 shares represented the public float. In accordance with the rules
Skybox Security and Exclusive Networks Announce New Partnership for Middle East Distribution of the Skybox Security Suite17.5.2018 18:41 | Pressemelding
The cybersecurity management platform ensures networks remain secure and compliant as organisations migrate to cloud and merge networks SAN JOSE, Calif., May 17, 2018 (GLOBE NEWSWIRE) -- Skybox(TM) Security, a global leader in cybersecurity management, announced today a new partnership with Exclusive Networks for distribution of Skybox solutions in the Middle East, including the Gulf Cooperation Council (GCC) region and Egypt. Exclusive Networks will deploy and service the Skybox(TM) Security Suite, a broad security management platform that provides comprehensive attack surface visibility and enables unified vulnerability management and firewall/security policy management across an organization's entire network, including in physical, multi-cloud and OT environments. "Driven by government outlays (with oil, gas and defence industries leading the charge), Middle East organisations are looking for trusted security advisors who can navigate digital transformations and reduce risks - espec
Dermatological Symposium Tackles the Effects of Pollution on Skin17.5.2018 16:03 | Pressemelding
Researchers Present Compelling Evidence Showing the Effects of Pollution on Skin Health at Symposium Sponsored by Mary Kay Inc. DALLAS, May 17, 2018 (GLOBE NEWSWIRE) -- Mary Kay Inc. announced four keynote speakers for its symposium to be held during the prestigious International Investigative Dermatology (IID) Meeting on May 16 to 19, 2018 in Orlando, Florida. The IID meeting occurs once every 5 years, and brings together scientists from across the globe, highlighting the latest in cutting edge science in dermatology. The Mary Kay sponsored Symposium features four global experts including Dr. Liang Liu, Assistant Professor of Dermatology, Columbia University; Dr. Max Costa, Professor and Chairman of the department of Environmental Medicine, New York University School of Medicine; Dr. Jean Krutmann, Chair of Environmental Medicine at the Medical Faculty of Heinrich Heine University Düsseldorf and Director of the Leibniz Research Institute of Environmental Medicine in Dusseldorf, German
Talend Opens Nomination Period for Data Masters Awards17.5.2018 14:21 | Pressemelding
Annual Program Showcases Customers' Innovative Use of Cloud Technologies for Digital Transformation REDWOOD CITY, Calif., May 17, 2018 (GLOBE NEWSWIRE) -- Talend (NASDAQ: TLND), a global leader in cloud and big data integration solutions, officially opened the submission period for its fourth annual Data Masters Awards. This program celebrates companies using Talend solutions in innovative, forward-thinking ways to put more data to work and enable more informed and impactful business decisions. Organizations interested in nominating a project can complete an official entry form here. Finalists will be chosen from Talend's more than 1,500 global customers representing large enterprises and private firms across all major industries including banking and insurance, consumer goods, healthcare, manufacturing and retail. Past award recipients include some of the world's best-known brands including: AIG, Air France/KLM, Beachbody, Citi, Credit Agricole Consumer Finance, GE Healthcare, HERMES
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom